Customs reports intercepting thousands of GLP-1 peptide shipments from China

U.S. Customs and Border Protection officers at the Port of Cincinnati report intercepting more than 300 "master carton" smuggling attempts from China between December 2025 and March 25, 2026, concealing roughly 5,000 individual, pre-labeled peptide shipments. The packages contained semaglutide, tirzepatide, and other GLP-1-related peptides such as retatrutide and cagrilintide, all mis-manifested to hide their true contents, according to a CBP press release dated March 31, 2026 ^[1].

The seizures are one piece of a broader enforcement push against the gray-market supply chain that feeds bulk peptide sold directly to patients. In September 2025, the FDA established an import alert that subjects GLP-1 active pharmaceutical ingredients from manufacturers not on its vetted "green list" to automatic detention at the border without physical examination, targeting the Chinese API makers that supply resellers and some compounders ^[1]. On February 6, 2026, FDA Commissioner Makary announced a broader crackdown on GLP-1 API importation and marketing, and on February 20, 2026, the agency issued 30 warning letters in a single day to telehealth companies over unlawful marketing of compounded GLP-1 products ^[1].

Enforcement has also reached prescribers. On April 1, 2026, a Utah osteopathic physician was federally indicted for allegedly buying unapproved peptides from China through a middleman and selling them to more than 200 patients, according to the U.S. Attorney's Office for the District of Utah and the Partnership for Safe Medicines ^[1]. Globally, INTERPOL's Operation Pangea XVIII, conducted March 10-23, 2026 across 90 countries, led to 269 arrests and the dismantling of 66 criminal organizations involved in online pharmacy fraud, with seizures valued at more than $15.5 million; among the seized products, authorities found sibutramine, a cardiovascular-risk appetite suppressant withdrawn from markets worldwide in 2010, mixed into products marketed as GLP-1 agonists ^[1].

The scale of the trade is driven by cost. A vial of bulk Chinese semaglutide or tirzepatide, enough for two to three months at clinical doses, commonly sells for $40 to $100, compared with $1,349 a month for branded Wegovy in the United States ^[1]. That price gap has fueled demand even though importing unapproved injectable medications for personal use is illegal under the Federal Food, Drug, and Cosmetic Act, which prohibits introducing unapproved drugs into interstate commerce ^[1].

Why it matters for patients

These seizures show that CBP and FDA enforcement against the gray-market peptide supply chain is intensifying, not easing off. While prosecution of individual buyers for personal-use quantities has historically been uncommon, the source material notes suppliers, resellers, prescribers, and now API importers face materially heavier legal risk, and the trend is toward escalation at every level of the chain ^[1].

Patients relying on gray-market peptide also face a safety information gap. Independent lab testing, such as HPLC purity analysis and mass spectrometry for identity, can confirm whether a vial contains the labeled molecule, how pure it is, and whether the dose matches the label — but it cannot confirm sterility or the absence of bacterial endotoxins, which require separate testing ^[1]. There is no published data on what share of gray-market products fail these tests, because samples sent to labs are self-selected by suspicious buyers, not a representative survey of the market ^[1].

There is also a practical medical consequence. If a complication arises from a self-administered unapproved injectable, disclosing that source during hospital treatment can create downstream insurance, employer, or reporting consequences in some jurisdictions, according to the source material ^[1].

What happens next

The CBP seizure figures cover shipments identified through March 25, 2026, with the press release issued March 31, 2026 ^[1]. The FDA's import alert on GLP-1 API manufacturers not on its green list remains in effect since September 2025, and the agency's February 2026 warning letters to telehealth companies signal continued scrutiny of compounded GLP-1 marketing ^[1]. No source in this report indicates a scheduled end date for the enforcement campaign.